Insulet (PODD) Stock Price & Analysis
Score
AI Analysis
SnapshotInsulet is a growth-led story right now — Growth 89/100 is the pillar doing the heavy lifting (overall 75/100) in Medical - Devices. Under the hood: P/E 25.2, about 66% below its own multi-year median, plus revenue compounding ~28% annually over recent years. Street targets still imply ~17% upside.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Insulet Corp. (PODD) last printed $154.86. Equity value is $10.27B. Trailing earnings multiple 23.95. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| $366.99M | $463.77M | $563.82M | $738.2M | $904.4M | $1.1B | $1.31B | $1.7B | $2.07B | $2.71B |
About
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.